This company is no longer active
AVROBIO Management
Management criteria checks 3/4
AVROBIO's CEO is Erik Ostrowski, appointed in Jan 2019, has a tenure of 5.42 years. total yearly compensation is $1.59M, comprised of 31.7% salary and 68.3% bonuses, including company stock and options. directly owns 0.065% of the company’s shares, worth $41.58K. The average tenure of the management team and the board of directors is 2.7 years and 6.2 years respectively.
Key information
Erik Ostrowski
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 31.71% |
| CEO tenure | 5.4yrs |
| CEO ownership | 0.07% |
| Management average tenure | 2.7yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK
Oct 18Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status
Sep 20AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy
Jul 13Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Nov 13
We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
Aug 10Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Mar 08We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth
Nov 23
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$30m |
| Dec 31 2023 | US$2m | US$504k | US$12m |
| Sep 30 2023 | n/a | n/a | -US$4m |
| Jun 30 2023 | n/a | n/a | -US$5m |
| Mar 31 2023 | n/a | n/a | -US$101m |
| Dec 31 2022 | US$1m | US$460k | -US$106m |
| Sep 30 2022 | n/a | n/a | -US$109m |
| Jun 30 2022 | n/a | n/a | -US$119m |
| Mar 31 2022 | n/a | n/a | -US$122m |
| Dec 31 2021 | US$3m | US$439k | -US$119m |
| Sep 30 2021 | n/a | n/a | -US$119m |
| Jun 30 2021 | n/a | n/a | -US$123m |
| Mar 31 2021 | n/a | n/a | -US$121m |
| Dec 31 2020 | US$2m | US$424k | -US$120m |
| Sep 30 2020 | n/a | n/a | -US$114m |
| Jun 30 2020 | n/a | n/a | -US$95m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$3m | US$412k | -US$73m |
Compensation vs Market: Erik's total compensation ($USD1.59M) is above average for companies of similar size in the US market ($USD683.56K).
Compensation vs Earnings: Erik's compensation has been consistent with company performance over the past year.
CEO
Erik Ostrowski (52 yo)
5.4yrs
Tenure
US$1,590,892
Compensation
Mr. Erik John Ostrowski, MBA, has been Chief Financial Officer and Treasurer at AVROBIO, Inc since January 2019 and served as its Principal Accounting Officer. He serves as President and Interim Chief Exec...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.4yrs | US$1.59m | 0.065% $ 41.6k | |
| Chief Technology Officer | 2.4yrs | US$1.27m | 0.084% $ 53.5k | |
| Chief Medical Officer | 2.7yrs | US$1.34m | 0.035% $ 22.5k | |
| Scientific Founder | no data | no data | no data | |
| Chief Legal Officer & Secretary | 5.4yrs | US$1.77m | 0.049% $ 31.3k | |
| Vice President of Human Resource | 2.4yrs | no data | no data | |
| Chief of Staff | no data | no data | no data |
2.7yrs
Average Tenure
48yo
Average Age
Experienced Management: AVRO's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 6.4yrs | US$63.97k | 0% $ 0 | |
| Independent Non-Employee Director | 6yrs | US$72.97k | 0.0044% $ 2.8k | |
| Independent Chairman of the Board | 8.3yrs | US$98.97k | 0% $ 0 | |
| Independent Director | 5.4yrs | US$73.97k | 0.011% $ 6.8k | |
| Director | 3.7yrs | US$61.47k | 0% $ 0 | |
| Independent Director | 6.2yrs | US$76.97k | 0% $ 0 | |
| Independent Director | 8.4yrs | US$72.97k | 0.56% $ 358.6k |
6.2yrs
Average Tenure
63yo
Average Age
Experienced Board: AVRO's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/20 01:55 |
| End of Day Share Price | 2024/06/20 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AVROBIO, Inc. is covered by 15 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yun Zhong | BTIG |
| Whitney Ijem | Guggenheim Securities, LLC |
| Debjit Chattopadhyay | H.C. Wainwright & Co. |